BeOne Medicines announces positive phase 3 trial results for cancer drugs Nov 17, 2025 06:00AM
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or M Nov 17, 2025 06:00AM
BeiGene to Present New Clinical Data on Tislelizumab at ESMO IO Congress 2021 Dec 2, 2021 03:00AM